Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
Home
Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
Next Post
Previous Post
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With
nab
-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
or
TSC2
Genes (PRECISION 1)
Long-term follow-up for duration of response (DOR) after weekly
nab
-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARROâ„¢ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of
nab
-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.